Zevra Therapeutics (ZVRA) announced organizational changes. The company announced that it is consolidating its development and scientific functions under Adrian Quartel, chief medical officer. Quartel will be responsible for clinical development, quality assurance, and regulatory and scientific affairs. As part of these changes, Christal Mickle, chief development officer, or CDO, and Sven Guenther, chief scientific officer, or CSO, are departing Zevra effective December 6 and December 23, respectively. The company has also eliminated positions in chemistry, manufacturing and controls and clinical development, consistent with the change in portfolio priorities.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease
- Zevra Therapeutics announces U.S. commercial availability of MIPLYFFA
- Zevra Therapeutics price target lowered to $23 from $25 at Canaccord
- Zevra Therapeutics’ Transformative Third Quarter 2024
- Zevra Therapeutics reports Q3 EPS (69c), consensus (42c)